“Cynomolgus monkey was selected as the appropriate animal species for assessing the nonclinical safety, pharmacokinetic (PK), and pharmacodynamic (PD) properties of mosunetuzumab and 2H7v16/40G5c.”
Cross-reacts with CD20 and CD3 in human and cynomolgus monkey, not rodents; comparable CD3 binding and B-cell killing potency
“2H7v16/40G5c displays the same properties as mosunetuzumab, as it cross-reacts with CD20 and CD3 in both humans and cynomolgus monkeys, but not in rodents.”
Yes: functionally equivalent E. coli-made precursor 2H7v16/40G5c used in early monkey studies; pivotal 26-week study used mosunetuzumab
“Mosunetuzumab is produced from Chinese hamster ovary (CHO) cells; the functionally equivalent antibody, referred to as 2H7v16/40G5c and the proof-of-concept (POC) molecule, referred to as 2H7v16/UCHT1v9, were produced from E. coli.”